In mid-June, the American College of Physicians — the professional society for internal medicine — published its first living clinical guideline on obesity medication, and put semaglutide and tirzepatide at the top of a four-drug hierarchy. Coverage of it read like a verdict: GLP-1s win. The guideline itself reads more like a set of open questions with a ranking attached, and the parts it leaves unresolved matter more than the ranking does.
What the guideline actually says
Published in Annals of Internal Medicine, the guideline sorts obesity pharmacotherapy into tiers for adults who aren’t pregnant.
For a BMI of 30 or higher:
- Semaglutide or tirzepatide (first-line)
- Phentermine-topiramate (second-line)
- Liraglutide (third-line)
- Naltrexone-bupropion (fourth-line)
For a BMI of 27 to 30 with a weight-related condition like diabetes or high blood pressure, the tiers collapse to two: semaglutide or tirzepatide first, liraglutide second.
The guideline calls itself “living” on purpose — ACP intends to revisit and update it as new trial data comes in, rather than treating this as a settled document. That framing is worth sitting with, because a field that updates its own top recommendation on a rolling basis is not one where “first-line” should be read as “case closed.”
What “first-line” does not decide
A tier list answers one question: on average, across a population, which drug class produced the best results in trials. It does not answer the question a patient and their provider actually have to answer, which is what to do for one person.
The guideline says so itself. ACP’s own list of what should factor into the actual decision includes benefits, harms, cost, access and availability, comorbidities, weight-loss goals, life expectancy, and personal values and preferences — a list explicitly longer than “which one ranked first.” A population-level ranking is an input to that conversation, not a replacement for it.
The guideline flags real unknowns, not settled facts. On the question of how long someone should stay on a GLP-1, ACP states plainly that the optimal duration of treatment is uncertain and that longer-term safety data are still needed. Reporting on the guideline also noted a companion warning: because weight tends to return after a medication is stopped, treating these drugs as a short course misreads what the evidence currently shows. Both of those are the guideline authors themselves saying the science isn’t finished — not something a critic is reading into it.
It comes with a side-effect counseling requirement, not a clean bill of health. The guideline specifically calls for discussing nutritional deficiencies and muscle and bone density loss, particularly in older adults, as part of prescribing any of these medications. A first-line ranking and a side-effect conversation are meant to happen together, not one instead of the other.
The part that applies to compounded medications
The trials behind this ranking, like essentially all GLP-1 trial evidence, tested manufactured branded semaglutide and tirzepatide — the products made directly by their manufacturers under an approved application. That’s what “first-line” refers to.
Compounded semaglutide and tirzepatide, the medications NoBsRx provides provider-guided access to, are prepared by state-licensed pharmacies for an individual patient. They are not FDA-approved products, and ACP’s guideline doesn’t evaluate them as a separate category. The active compound is the same one under study; the specific compounded preparation is not something this guideline, or the trials feeding it, tested directly.
Why a ranking is a starting point, not a prescription
None of this makes the guideline wrong. It’s a genuinely useful summary of where the trial evidence currently points, and it’s honest — more honest than most marketing built around it — about how much is still unsettled: duration, long-term safety, and who actually benefits most from which tier.
That’s the argument for treatment that starts with your labs and history instead of a chart ranking. How our process works is built around a licensed provider reviewing your specific case — including the access and comorbidity questions ACP lists as part of the real decision — rather than defaulting to whatever ranked first in a population average you weren’t part of. The cost question is one we don’t make you wait to ask: every program’s price is published up front, not routed through a quiz first. A guideline can tell a provider where to start looking. It can’t tell them what’s right for the person in front of them.
This post is general information, not medical advice. It does not describe a guaranteed benefit or outcome of any NoBsRx program. Compounded medications are not FDA-approved. Treatment is never guaranteed — eligibility, diagnosis, and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any medication based on an article. Talk to a licensed provider about what fits your own health history.